Vista Pharma Peer Comparison

BSE: 524711

₹5.93

₹-0.18 (-2.95%)

As on 21-Oct-2026IST

Market cap

₹37 Cr

Revenue (TTM)

₹4 Cr

P/E Ratio

--

P/B Ratio

1

Div. Yield

0 %

Edit

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	37	30,460	25,442	25,846	24,007
Revenue (₹ Cr)	4	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	-11.76	414.00	-371.81	387.35	288.22
Net Margin (%)	-277.62	11.23	-3.93	26.01	14.79
RoE (%)	-29.00	8.38	-3.85	25.18	29.77
Price to Earnings	--	74.47	--	66.92	83.30
Price-To-Book	1.03	6.05	3.18	14.98	17.88

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	3.88	3,564.00	9,205.28	1,461.80	1,935.80
Total Income	4.24	3,686.00	9,449.59	1,489.25	1,948.58
Total Expenditure	18.23	2,792.00	8,195.15	919.25	1,485.56
EBITDA	-14.35	772.00	1,010.13	542.56	450.24
Depreciation	0.76	226.00	857.51	37.68	50.83
EBIT	-15.11	546.00	152.62	504.88	399.41
Interest	1.24	217.00	342.73	3.77	40.84
Other Income	0.36	122.00	244.31	27.45	12.78
Exceptional Items	0.00	12.00	-216.88	0.00	0.00
Profit before Tax	-16.00	463.00	-162.68	528.56	371.35
Provision for Tax	-4.24	49.00	209.13	141.21	83.14
Profit after Tax	-11.76	414.00	-371.81	387.35	288.22

Liabilities (₹ Cr)

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	36.44	4,940.00	8,162.62	1,653.56	1,288.82
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	2.00	1,712.00	5,044.14	42.40	202.03
Current Liabilities	16.65	1,622.00	4,758.28	230.82	835.87
Total Liabilities	60.29	8,100.00	15,513.53	1,549.26	1,451.43

Assets (₹ Cr)

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	37.37	5,343.00	10,211.52	1,026.85	519.60
Current Assets	15.36	2,606.00	7,191.66	881.27	1,681.81
Total Assets	60.29	8,100.00	15,513.53	1,549.26	1,451.43
Total Debt*	7.40	1,859.00	4,720.27	8.18	393.17
Net Current Assets	-1.28	984.00	2,433.38	650.46	845.94
Contingent Liabilities	--	770.26	99.76	15.38	12.25

Cashflow (₹ Cr)

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	-6.98	-22.00	892.30	118.34	159.18
Cash Flow from Investing Activities	-0.44	-783.00	-477.46	-223.94	-64.81
Cash from Financing Activities	8.06	409.00	-440.83	261.12	-39.81
Net Cash Inflow / Outflow	0.64	-396.00	-25.99	155.52	54.56

Ratios

Profitability Ratios

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	-8.54	4.07	6.61	20.14	26.97
ROE (%)	-29.00	8.38	-3.85	25.18	29.77
ROA (%)	-20.38	4.94	-2.21	21.93	24.77
EBIT Margin (%)	-389.43	15.32	1.66	34.54	20.63
Net Margin (%)	-277.62	11.23	-3.93	26.01	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	-60.40	18.37	0.78	40.90	46.65
EBIT Growth (%)	-196.62	252.26	-70.53	124.50	62.13
Net Profit Growth (%)	-131.35	377.85	-1,383.43	104.15	89.49
EPS Growth (%)	-131.35	1,001.33	-484.84	42.32	78.60
Book Value Growth (%)	27.38	29.77	2.28	94.96	42.49

Valuation Ratios

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	-3.10	76.44	-81.31	66.92	82.01
Price / Book Value	1.03	6.05	3.18	14.98	17.88
Dividend Yield (%)	0.00	0.00	0.00	0.08	0.10
EV/EBITDA	-3.01	41.35	29.29	47.27	53.13
Market Cap (₹ Cr)	66.11	23,064.69	29,731.27	19,988.69	0.00

Solvency Ratios

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.05	0.31	0.53	0.01	0.11
Short term debt to equity ratio	0.11	0.11	0.12	0.02	0.54
Current Ratio	0.92	1.61	1.51	3.82	2.01
Quick Ratio	0.26	1.06	0.87	2.82	1.14
Interest Coverage	-11.86	3.13	0.53	141.16	10.09

Operating Efficiency Ratios

	Vista Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	8.17	16.50	23.44	24.80	26.28
Asset Turnover	0.07	0.43	0.55	0.83	1.66
Receivable days	137.33	60.36	77.05	90.06	47.59
Inventory Days	271.84	64.42	77.13	61.02	62.58
Payable days	284.27	218.94	173.49	96.06	228.78
Cash Conversion Cycle	124.89	-94.15	-19.30	55.02	-118.62

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly